Noelle K. LoConte, MD close
Noelle K. LoConte, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Noelle K. LoConte, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. LoConte is an associate professor of medicine at the University of Wisconsin. She completed medical school at the University of Illinois at Chicago, then did her internship in internal medicine at UW. Dr. LoConte completed her internal medicine residency at Oregon Health Sciences University in Portland. She has also completed fellowship training in both medical oncology as well as geriatrics. She joined the faculty of the UW Carbone Cancer Center in the summer of 2006. She is the recipient of the American Society of Clinical Oncology Young Investigator Award for 2006, and has funding from the Centers for Disease Control and the National Cancer Institute.  She has been a principal investigator on many clinical trials of new chemotherapies for gastrointestinal cancers, from Phase I through Phase III studies.  Dr. LoConte is also the co-leader of the UW Carbone Cancer Center gastrointestinal disease oriented working group. Dr. LoConte's clinical interests are in gastrointestinal cancers, including liver and pancreas cancers, as well as cancer of any type in the older adult.



UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency Oregon Health and Science University Hospital, Portland, OR
Internship University of Wisconsin Hospital and Clinics, Madison, WI

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. LoConte's research interests are in predictors of chemotherapy toxicity, as well as trials of chemotherapy in older adults and patients with gastrointestinal cancers.

PubMed Articles
Hu ZI Bendell JC Bullock A LoConte NK Hatoum H Ritch P Hool H Leach JW Sanchez J Sohal DPS Strickler J Patel R Wang-Gillam A Firdaus I Yu KH Kapoun AM Holmgren E Zhou L Dupont J Picozzi V Sahai V O'Reilly EM A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med . 2019 Jul 26;
[PubMed ID: 31347292]
Le DT Picozzi VJ Ko AH Wainberg ZA Kindler H Wang-Gillam A Oberstein P Morse MA Zeh HJ 3rd Weekes C Reid T Borazanci E Crocenzi T LoConte NK Musher B Laheru D Murphy A Whiting C Nair N Enstrom A Ferber S Brockstedt DG Jaffee EM Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res . 2019 May 24;
[PubMed ID: 31126960]
Guerard EJ Harmon GE Sahasrabudhe KD LoConte NK Recent advances in non-surgical management of cancer in the elderly. F1000Res . 2018;7
[PubMed ID: 30505429]
Engle JA Traynor AM Campbell TC Wisinski KB LoConte N Liu G Wilding G Kolesar JM Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract . 2018 Jul;24(5):348-353
[PubMed ID: 28457192]
Mak LY Cruz-Ramón V Chinchilla-López P Torres HA LoConte NK Rice JP Foxhall LE Sturgis EM Merrill JK Bailey HH Méndez-Sánchez N Yuen MF Hwang JP Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book . 2018 May 23;38:262-279
[PubMed ID: 30231359]
LoConte NK Gershenwald JE Thomson CA Crane TE Harmon GE Rechis R Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. Am Soc Clin Oncol Educ Book . 2018 May 23;38:88-100
[PubMed ID: 30231343]
LoConte NK Brewster AM Kaur JS Merrill JK Alberg AJ Alcohol and Cancer: A Statement of the American Society of Clinical Oncology. J Clin Oncol . 2018 Jan 1;36(1):83-93
[PubMed ID: 29112463]
Mroz S Zhang X Williams M Conlon A LoConte NK Working to Increase Vaccination for Human Papillomavirus: A Survey of Wisconsin Stakeholders, 2015. Prev Chronic Dis . 2017 Sep 28;14:E85
[PubMed ID: 28957034]
Martin RL Tully M Kos A Frazer D Williamson A Conlon A Enser JJ LoConte NK Increasing Colorectal Cancer Screening at an Urban FQHC Using iFOBT and Patient Navigation. Health Promot Pract . 2017 Sep;18(5):741-750
[PubMed ID: 28812930]
Robins HI Johnson L LoConte N Brandt K Cancer-related cognitive impairment and its relation to PTSD. Breast . 2017 Aug;34:134
[PubMed ID: 28285890]
Yao JC Guthrie KA Moran C Strosberg JR Kulke MH Chan JA LoConte N McWilliams RR Wolin EM Mattar B McDonough S Chen H Blanke CD Hochster HS Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol . 2017 May 20;35(15):1695-1703
[PubMed ID: 28384065]
Neuman HB Rathouz PJ Winslow E Weiss JM LoConte NK Lin CP Wurm M Smith MA Schrag D Greenberg CC Use of a novel statistical technique to examine the delivery of breast cancer follow-up care by different types of oncology providers. J Eval Clin Pract . 2016 Oct;22(5):737-44
[PubMed ID: 26991311]
Decker MR Trentham-Dietz A Loconte NK Neuman HB Smith MA Punglia RS Greenberg CC Wilke LG The Role of Intraoperative Pathologic Assessment in the Surgical Management of Ductal Carcinoma In Situ. Ann Surg Oncol . 2016 Sep;23(9):2788-94
[PubMed ID: 27026436]
Sievers CK Kratz JD Zurbriggen LD LoConte NK Lubner SJ Uboha N Mulkerin D Matkowskyj KA Deming DA The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clin Colon Rectal Surg . 2016 Sep;29(3):232-8
[PubMed ID: 27582648]
Katz MH Shi Q Ahmad SA Herman JM Marsh Rde W Collisson E Schwartz L Frankel W Martin R Conway W Truty M Kindler H Lowy AM Bekaii-Saab T Philip P Talamonti M Cardin D LoConte N Shen P Hoffman JP Venook AP Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg . 2016 Aug 17;151(8):e161137
[PubMed ID: 27275632]
Jin N Lubner SJ Mulkerin DL Rajguru S Carmichael L Chen H Holen KD LoConte NK A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist . 2016 Jul;21(7):785-6
[PubMed ID: 27261467]
Deming DA Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Eickhoff JC Kolesar JM Fioravanti S Greten TF Compton K Doyle AG Wilding G Duffy A Liu G A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs . 2016 Apr;34(2):168-75
[PubMed ID: 26666244]
Ko AH LoConte N Tempero MA Walker EJ Kate Kelley R Lewis S Chang WC Kantoff E Vannier MW Catenacci DV Venook AP Kindler HL A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas . 2016 Mar;45(3):370-5
[PubMed ID: 26390428]
Tran NH Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Clipson L Matkowskyj KA Deming DA Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol . 2015 Sep;7(5):252-62
[PubMed ID: 26327923]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol . 2015 Aug;76(2):317-23
[PubMed ID: 26068189]